Butyrate and colorectal cancer: The role of butyrate transport

Current Drug Metabolism

Volumn 14, Issue 9, 2013, Pages 994-1008

  Gonçalves, Pedro ^a   Martel, Fátima ^a  

^a University of Porto   (Portugal)

Author keywords

Absorption; BCRP; Butyrate; Colorectal cancer; Dietary fiber; MCT1; SMCT1; Xenobiotics

Indexed keywords

2 PHENOXYBUTYRATE; 3 PHENYLBUTYRATE; 4 PHENYLBUTYRIC ACID; AMPHETAMINIL; AN 7; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; BUTYRYL LEVO CARNITINE; CARNITINE; CARRIER PROTEINS AND BINDING PROTEINS; CINNAMIC ACID; CYCLOOXYGENASE 2; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOXYCINNAMATE; MICRORNA; MICRORNA 106B; MONOCARBOXYLATE TRANSPORTER 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENOXYACETIC ACID; PIVALOYLOXYMETHYL BUTYRATE; PMX 550D; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; PXM 550B; SHORT CHAIN FATTY ACID; SODIUM COUPLED MONOCARBOXYLATE TRANSPORTER 1; TRIBUTYRIN; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CHEMOPROPHYLAXIS; CHRONIC LYMPHATIC LEUKEMIA; COLON CARCINOGENESIS; COLON MUCOSA; COLONOSCOPY; COLORECTAL CANCER; DIETARY FIBER; DOWN REGULATION; DRUG HALF LIFE; DRUG TRANSPORT; ENTERITIS; FIRST PASS EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE OVEREXPRESSION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; INTESTINE ABSORPTION; LIVER CLEARANCE; MELANOMA; MEMBRANE TRANSPORT; METASTASIS INHIBITION; NONHUMAN; ONCOGENE C MYC; ONCOGENE SRC; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BIOLOGICAL TRANSPORT; BUTYRATES; COLORECTAL NEOPLASMS; HUMANS; INTESTINES;

EID: 84887903682     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211314090006     Document Type: Article

References (270)

1. Heron, M. Deaths: leading causes for 2008. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl. Vital Stat. Rep., 2012, 60, 1-94.
2. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin., 2010, 60, 277-300.
3. Ferro, S. A.; Myer, B. S.; Wolff, D. A.; Poniewierski, M. S.; Culakova, E.; Cosler, L. E.; Scarpace, S. L.; Khorana, A. A.; Lyman, G. H. Variation in the cost of medications for the treatment of colorectal cancer. Am. J. Manag. Care, 2008, 14, 717-25.
4. Acheson, A. G.; Scholefield, J. H. Survival from cancers of the colon and rectum in England and Wales up to 2001. Br. J. Cancer, 2008, 99 Suppl 1, S33-4.
5. Benson, A. B. 3rd. Epidemiology, disease progression, and economic burden of colorectal cancer. J. Manag. Care Pharm., 2007, 13, S5-18.
6. de Jong, A. E.; Vasen, H. F. The frequency of a positive family history for colorectal cancer: a population-based study in the Netherlands. Neth. J. Med., 2006, 64, 367-70.
7. Armstrong, B.; Doll, R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int. J. Cancer., 1975, 15, 617-31.
8. Kono, S. Secular trend of colon cancer incidence and mortality in relation to fat and meat intake in Japan. Eur. J. Cancer Prev., 2004, 13, 127-32.
9. Khuhaprema, T.; Srivatanakul, P. Colon and rectum cancer in Thailand: an overview. Jpn. J. Clin. Onco.,2008, 38, 237-43.
10. Terry, P.; Giovannucci, E.; Michels, K. B.; Bergkvist, L.; Hansen, H.; Holmberg, L.; Wolk, A. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J. Natl. Cancer Inst., 2001, 93, 525-533.
11. Young, G. P.; Hu, Y.; Le Leu, R. K.; Nyskohus, L. Dietary fibre and colorectal cancer: A model for environment-gene interactions. Mol. Nutr. Food Res., 2005, 49, 571-584.
12. Shannon, J.; White, E.; Shattuck, A. L.; Potter, J. D. Relationship of food groups and water intake to colon cancer risk. Cancer Epidemiol. Biomarkers Prev., 1996, 5, 495-502.
13. Ahmed, F. E. Effect of diet, life style, and other environmental/ chemopreventive factors on colorectal cancer development, and assessment of the risks. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev., 2004, 22, 91-147.
14. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 1992, 52, 5575-89.
15. Potter, J. D. Colorectal cancer: molecules and populations. J Natl Cancer Inst., 1999, 91, 916-32.
16. Fearnhead, N. S.; Wilding, J. L.; Bodmer, W. F. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Brit. Med. Bull., 2002, 64, 27-43.
17. Pino, M. S.; Chung, D. C. The chromosomal instability pathway in colon cancer. Gastroenterology, 2010, 138, 2059-72.
18. Hoff, G.; Vatn, M. H. Colonic adenoma: natural history. Dig. Dis., 1991, 9, 61-9.
19. Rex, D. K.; Johnson, D. A.; Anderson, J. C.; Schoenfeld, P. S.; Burke, C. A.; Inadomi, J. M. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J. Gastroenterol., 2009, 104, 739-50.
20. Rex, D. K.; Petrini, J. L.; Baron, T. H.; Chak, A.; Cohen, J.; Deal, S. E.; Hoffman, B.; Jacobson, B. C.; Mergener, K.; Petersen, B. T.; Safdi, M. A.; Faigel, D. O.; Pike, I. M. Quality indicators for colonoscopy. Am. J. Gastroenterol., 2006, 101, 873-85.
21. Singh, H.; Nugent, Z.; Demers, A. A.; Kliewer, E. V.; Mahmud, S. M.; Bernstein, C. N. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology, 2010, 139, 1128-1137.
22. Mathew, A.; Peters, U.; Chatterjee, N.; Kulldorff, M.; Sinha, R. Fat, fiber, fruits, vegetables, and risk of colorectal adenomas. Int. J. Cancer, 2004, 108, 287-92.
23. Das, D.; Arber, N.; Jankowski, J. A. Chemoprevention of colorectal cancer. Digestion, 2007, 76, 51-67.
24. Herszenyi, L.; Farinati, F.; Miheller, P.; Tulassay, Z. Chemoprevention of colorectal cancer: feasibility in everyday practice? Eur. J. Cancer Prev., 2008, 17, 502-14.
25. Burkitt, D. P. Epidemiology of cancer of the colon and rectum. Cancer, 1971, 28, 3-13.
26. Topping, D. L.; Clifton, P. M. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev., 2001, 81, 1031-64.
27. Hallert, C.; Bjorck, I.; Nyman, M.; Pousette, A.; Granno, C.; Svensson, H. Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm. Bowel Dis., 2003, 9, 116-21.
28. Guilloteau, P.; Martin, L.; Eeckhaut, V.; Ducatelle, R.; Zabielski, R.; Van Immerseel, F. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr. Res. Rev., 2010, 23, 366-84.
29. Hamer, H. M.; Jonkers, D.; Venema, K.; Vanhoutvin, S.; Troost, F. J.; Brummer, R. J. Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther., 2008, 27, 104-19.
30. Manning, T. S.; Gibson, G. R. Microbial-gut interactions in health and disease. Prebiotics. Best Pract. Res. Clin. Gastroenterol., 2004, 18, 287-98.
31. McIntyre, A.; Gibson, P. R.; Young, G. P. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut, 1993, 34, 386-91.
32. Goncalves, P.; Martel, F.; Araujo, J. R.; Pinho, M. J. In vitro studies on the inhibition of colon cancer by butyrate and polyphenolic compounds. Nutr. Cancer, 2011, 63, 282-294.
33. Hague, A.; Elder, D. J.; Hicks, D. J.; Paraskeva, C. Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int. J. Cancer, 1995, 60, 400-6.
34. D'Argenio, G.; Cosenza, V.; Delle Cave, M.; Iovino, P.; Delle Valle, N.; Lombardi, G.; Mazzacca, G. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastroenterology, 1996, 110, 1727-34.
35. Kameue, C.; Tsukahara, T.; Yamada, K.; Koyama, H.; Iwasaki, Y.; Nakayama, K.; Ushida, K. Dietary sodium gluconate protects rats from large bowel cancer by stimulating butyrate production. J. Nutr., 2004, 134, 940-4.
36. Medina, V.; Afonso, J. J.; Alvarez-Arguelles, H.; Hernandez, C.; Gonzalez, F. Sodium butyrate inhibits carcinoma development in a 1,2-dimethylhydrazine-induced rat colon cancer. JPEN J. Parenter. Enteral. Nutr., 1998, 22, 14-7.
37. Lu, Y.; Nakanishi, T.; Tamai, I. Functional cooperation of SMCTs and URAT1 for renal reabsorption transport of urate. Drug Metab. Pharmacokinet., 2013, 28, 153-8
38. Gopal, E.; Miyauchi, S.; Martin, P. M.; Ananth, S.; Roon, P.; Smith, S. B.; Ganapathy, V. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharmaceut. Res., 2007, 24, 575-84.
39. Gopal, E.; Fei, Y. J.; Sugawara, M.; Miyauchi, S.; Zhuang, L.; Martin, P.; Smith, S. B.; Prasad, P. D.; Ganapathy, V. Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate. J. Biol. Chem., 2004, 279, 44522-32.
40. Bingham, S. A.; Day, N. E.; Luben, R. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study (vol 361, pg 1496, 2003). Lancet, 2003, 362, 1000-1000.
41. Clausen, M. R.; Bonnen, H.; Mortensen, P. B. Colonic fermentation of dietary fiber to short chain fatty-acids in patients with adenomatous polyps and colonic-cancer. Gut, 1991, 32, 923-928.
42. Li, H.; Myeroff, L.; Smiraglia, D.; Romero, M. F.; Pretlow, T. P.; Kasturi, L.; Lutterbaugh, J.; Rerko, R. M.; Casey, G.; Issa, J. P.; Willis, J.; Willson, J. K. V.; Plass, C.; Markowitz, S. D. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 8412-8417.
43. Lambert, D. W.; Wood, I. S.; Ellis, A.; Shirazi-Beechey, S. P. Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J. Cancer, 2002, 86, 1262-9.
44. Comalada, M.; Bailon, E.; de Haro, O.; Lara-Villoslada, F.; Xaus, J.; Zarzuelo, A.; Galvez, J. The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J. Cancer Res. Clin., 2006, 132, 487-497.
45. Darzynkiewicz, Z.; Traganos, F.; Xue, S. B.; Melamed, M. R. Effect of n-butyrate on cell cycle progression and in situ chromatin structure of L1210 cells. Exp. Cell Res., 1981, 136, 279-93.
46. Foss, F. M.; Veillette, A.; Sartor, O.; Rosen, N.; Bolen, J. B. Alterations in the expression of pp60c-src and p56lck associated with butyrate-induced differentiation of human colon carcinoma cells. Oncogene Res., 1989, 5, 13-23.
47. Souleimani, A.; Asselin, C. Regulation of c-myc expression by sodium butyrate in the colon carcinoma cell line Caco-2. FEBS, Lett., 1993, 326, 45-50.
48. Siavoshian, S.; Blottiere, H. M.; Cherbut, C.; Galmiche, J. P. Butyrate stimulates cyclin D and p21 and inhibits cyclin-dependent kinase 2 expression in HT-29 colonic epithelial cells. Biochem. Biophys. Res. Commun., 1997, 232, 169-72.
49. Siavoshian, S.; Blottiere, H. M.; Le Foll, E.; Kaeffer, B.; Cherbut, C.; Galmiche, J. P. Comparison of the effect of different short chain fatty acids on the growth and differentiation of human colonic carcinoma cell lines in vitro. Cell Biol. Int., 1997, 21, 281-7.
50. Hu, S.; Dong, T. S.; Dalal, S. R.; Wu, F.; Bissonnette, M.; Kwon, J. H.; Chang, E. B. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One, 2011, 6, e16221.
51. Kilner, J.; Waby, J. S.; Chowdry, J.; Khan, A. Q.; Noirel, J.; Wright, P. C.; Corfe, B. M.; Evans, C. A. A proteomic analysis of differential cellular responses to the short-chain fatty acids butyrate, valerate and propionate in colon epithelial cancer cells. Mol. Biosyst., 2012, 8, 1146-56.
52. Pajak, B.; Gajkowska, B.; Orzechowski, A. Sodium butyrate sensitizes human colon adenocarcinoma COLO 205 cells to both intrinsic and TNF-alpha-dependent extrinsic apoptosis. Apoptosis, 2009, 14, 203-217.
53. Ruemmele, F. M.; Schwartz, S.; Seidman, E. G.; Dionne, S.; Levy, E.; Lentze, M. J. Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut, 2003, 52, 94-100.
54. Zgouras, D.; Wachtershauser, A.; Frings, D.; Stein, J. Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1 alpha nuclear translocation. Biochem. Biophys. Res. Commun., 2003, 300, 832-838.
55. Yu, D. C. W.; Waby, J. S.; Chirakkal, H.; Staton, C. A.; Corfe, B. M. Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. Mol. Cancer, 2010, 9, 276.
56. Joseph, J.; Mudduluru, G.; Antony, S.; Vashistha, S.; Ajitkumar, P.; Somasundaram, K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene, 2004, 23, 6304-6315.
57. Kaneko, F.; Saito, H.; Saito, Y.; Wakabayashi, K.; Nakamoto, N.; Tada, S.; Suzuki, H.; Tsunematsu, S.; Kumagai, N.; Ishii, H. Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int. J. Oncol., 2004, 24, 837-845.
58. Pan, M. H.; Ho, C. T. Chemopreventive effects of natural dietary compounds on cancer development. Chem. Soc. Rev., 2008, 37, 2558-2574.
59. Rosignoli, P.; Fabiani, R.; De Bartolomeo, A.; Spinozzi, F.; Agea, E.; Pelli, M. A.; Morozzi, G. Protective activity of butyrate on hydrogen peroxide-induced DNA damage in isolated human colonocytes and HT29 tumour cells. Carcinogenesis, 2001, 22, 1675-80.
60. Abrahamse, S. L.; Pool-Zobel, B. L.; Rechkemmer, G. Potential of short chain fatty acids to modulate the induction of DNA damage and changes in the intracellular calcium concentration by oxidative stress in isolated rat distal colon cells. Carcinogenesis, 1999, 20, 629-634.
61. Rodriguez-Cabezas, M. E.; Galvez, J.; Lorente, M. D.; Concha, A.; Camuesco, D.; Azzouz, S.; Osuna, A.; Redondo, L.; Zarzuelo, A. Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J. Nutr., 2002, 132, 3263-71.
62. Ebert, M. N.; Klinder, A.; Peters, W. H.; Schaferhenrich, A.; Sendt, W.; Scheele, J.; Pool-Zobel, B. L. Expression of glutathione Stransferases (GSTs) in human colon cells and inducibility of GSTM2 by butyrate. Carcinogenesis, 2003, 24, 1637-44.
63. Yaku, K.; Enami, Y.; Kurajyo, C.; Matsui-Yuasa, I.; Konishi, Y.; Kojima-Yuasa, A. The enhancement of phase 2 enzyme activities by sodium butyrate in normal intestinal epithelial cells is associated with Nrf2 and p53. Mol. Cell Biochem., 2012, 370, 7-14.
64. Yano, S.; Tierney, D. F. Butyrate increases catalase activity and protects rat pulmonary artery smooth muscle cells against hyperoxia. Biochem. Biophys. Res. Commun., 1989, 164, 1143-8.
65. Coxhead, J. M.; Williams, E. A.; Mathers, J. C. DNA mismatch repair status may influence anti-neoplastic effects of butyrate. Biochem. Soc. T., 2005, 33, 728-729.
66. Dronamraju, S. S.; Coxhead, J. M.; Kelly, S. B.; Mathers, J. C. Role of DNA-mismatch repair in anti-neoplastic effects of butyrate. Proc. Nutr. Soc., 2008, 67, E87.
67. Burstein, E.; Fearon, E. R. Colitis and cancer: a tale of inflammatory cells and their cytokines. J. Clin. Invest., 2008, 118, 464-467.
68. Zimmerman, M. A.; Singh, N.; Martin, P. M.; Thangaraju, M.; Ganapathy, V.; Waller, J. L.; Shi, H.; Robertson, K. D.; Munn, D. H.; Liu, K. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 302, G1405-15.
69. Place, R. F.; Noonan, E. J.; Giardina, C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: Downregulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem. Pharmacol., 2005, 70, 394-406.
70. Segain, J. P.; de la Bletiere, D. R.; Bourreille, A.; Leray, V.; Gervois, N.; Rosales, C.; Ferrier, L.; Bonnet, C.; Blottiere, H. M.; Galmiche, J. P., Butyrate inhibits inflammatory responses through NF kappa B inhibition: implications for Crohn's disease. Gut, 2000, 47, 397-403.
71. Kinoshita, M.; Suzuki, Y.; Saito, Y. Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. Biochem. Biophys. Res. Commun., 2002, 293, 827-31.
72. Schwab, M.; Reynders, V.; Ulrich, S.; Zahn, N.; Stein, J.; Schroder, O. PPAR gamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis, 2006, 11, 1801-1811.
73. Tong, X.; Yin, L.; Giardina, C. Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochem. Biophys. Res. Commun., 2004, 317, 463-471.
74. Jahns, F.; Wilhelm, A.; Jablonowski, N.; Mothes, H.; Radeva, M.; Wölfert, A.; Greulich, K. O.; Glei, M. Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue. Carcinogenesis, 2011, 32, 913-20.
75. Mariadason, J. M. HDACs and HDAC inhibitors in colon cancer. Epigenetics., 2008, 3, 28-37.
76. Ashktorab, H.; Belgrave, K.; Hosseinkhah, F.; Brim, H.; Nouraie, M.; Takkikto, M.; Hewitt, S.; Lee, E. L.; Dashwood, R. H.; Smoot, D. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig. Dis. Sci., 2009, 54, 2109-17.
77. Stypula-Cyrus, Y.; Damania, D.; Kunte, D. P.; Cruz, M. D.; Subramanian, H.; Roy, H. K.; Backman, V. HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One, 2013, 8, e64600
78. Mehnert, J. M.; Kelly, W. K. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J., 2007, 13, 23-9.
79. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer., 2001, 1, 194-202.
80. Davie, J. R. Inhibition of histone deacetylase activity by butyrate. J. Nutr., 2003, 133, 2485s-2493s.
81. Sekhavat, A.; Sun, J. M.; Davie, J. R. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Bio-Chem. Cell Biol., 2007, 85, 751-8.
82. Ito, T. Role of histone modification in chromatin dynamics. J Biochem., 2007, 141, 609-614.
83. de Haan, J. B.; Gevers, W.; Parker, M. I. Effects of sodium butyrate on the synthesis and methylation of DNA in normal cells and their transformed counterparts. Cancer Res., 1986, 46, 713-6.
84. Mizzen, C. A.; Pesavento, J. J.; Yang, H.; Kelleher, N. L. Certain and progressive methylation of histone H4 at lysine 20 during the cell cycle. Mol. Cell Biol., 2008, 28, 468-486.
85. White, N. R.; Mulligan, P.; King, P. J.; Sanderson, I. R. Sodium butyrate-mediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells. J. Pediatr. Gastr. Nutr., 2006, 42, 134-141.
86. Ranganna, K.; Mathew, O. P.; Yatsu, F. M. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells. Biomed. Pharmacother., 2010, 64, 733-740.
87. Zhang, H.; Li, W.; Nan, F.; Ren, F.; Wang, H.; Xu, Y.; Zhang, F. MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line. Biochem. Biophys. Res. Commun., 2011, 404, 273-8.
88. Basson, M. D.; Hong, F. Tyrosine kinase inhibitors reverse butyrate stimulation of human Caco-2 intestinal epithelial cell alkaline phosphatase but not butyrate promotion of dipeptidyl dipeptidase. Cell Biol. Int., 1998, 22, 339-344.
89. Orchel, A.; Dzierzewicz, Z.; Parfiniewicz, B.; Weglarz, L.; Wilczok, T. Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent. Dig. Dis. Sci., 2005, 50, 490-498.
90. Kopp, R.; Fichter, M.; Assert, R.; Pfeiffer, A. F.; Classen, S. Butyrate-induced alterations of phosphoinositide metabolism, protein kinase C activity and reduced CD44 variant expression in HT-29 colon cancer cells. Int. J. Mol.Med., 2009, 23, 639-649.
91. Ganapathy, V.; Thangaraju, M.; Cresci, G. A.; Liu, K.; Ananth, S.; Gnanaprakasam, J. P.; Browning, D. D.; Mellinger, J. D.; Smith, S. B.; Digby, G. J.; Lambert, N. A.; Prasad, P. D. GPR109A is a Gprotein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res., 2009, 69, 2826-2832.
92. Brown, A. J.; Goldsworthy, S. M.; Barnes, A. A.; Eilert, M. M.; Tcheang, L.; Daniels, D.; Muir, A. I.; Wigglesworth, M. J.; Kinghorn, I.; Fraser, N. J.; Pike, N. B.; Strum, J. C.; Steplewski, K. M.; Murdock, P. R.; Holder, J. C.; Marshall, F. H.; Szekeres, P. G.; Wilson, S.; Ignar, D. M.; Foord, S. M.; Wise, A.; Dowell, S. J. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem., 2003, 278, 11312-11319.
93. Hirasawa, A.; Hara, T.; Katsuma, S.; Adachi, T.; Tsujimoto, G. Free fatty acid receptors and drug discovery. Biol. Pharm. Bull., 2008, 31, 1847-1851.
94. Nilsson, N. E.; Kotarsky, K.; Owman, C.; Olde, B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem. Biophys. Res. Commun., 2003, 303, 1047-52.
95. Karaki, S.; Mitsui, R.; Hayashi, H.; Kato, I.; Sugiya, H.; Iwanaga, T.; Furness, J. B.; Kuwahara, A. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res., 2006, 324, 353-360.
96. Nie, D. T.; Tang, Y.; Chen, Y. K.; Jiang, H. M.; Robbins, G. T. Gprotein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int. J. Cancer, 2011, 128, 847-856.
97. Novogrodsky, A.; Dvir, A.; Ravid, A.; Shkolnik, T.; Stenzel, K. H.; Rubin, A. L.; Zaizov, R. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer., 1983, 51, 9-14.
98. Oki, Y.; Issa, J. P. Review: recent clinical trials in epigenetic therapy. Rev. Recent Clin. Trials, 2006, 1, 169-82
99. Steliou, K.; Boosalis, M. S.; Perrine, S. P.; Sangerman, J.; Faller, D. V. Butyrate histone deacetylase inhibitors. Biores. Open Access, 2012, 1, 192-8.
100. Lea, M. A.; Randolph, V. M.; Hodge, S. K. Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res., 1999, 19, 1971-6.
101. Entin-Meer, M.; Rephaeli, A.; Yang, X.; Nudelman, A.; Vanden-Berg, S. R.; Haas-Kogan, D. A. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol. Cancer Ther., 2005, 4, 1952-61.
102. Blank-Porat, D.; Gruss-Fischer, T.; Tarasenko, N.; Malik, Z.; Nudelman, A.; Rephaeli, A. The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. Cancer Lett., 2007, 256, 39-48.
103. Tarasenko, N.; Kessler-Icekson, G.; Boer, P.; Inbal, A.; Schlesinger, H.; Phillips, D. R.; Cutts, S. M.; Nudelman, A. Rephaeli, A. The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Invest. New Drugs, 2012, 30, 130-43.
104. Reid, T.; Valone, F.; Lipera, W.; Irwin, D.; Paroly, W.; Natale, R.; Sreedharan, S.; Keer, H.; Lum, B.; Scappaticci, F.; Bhatnagar, A. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer, 2004, 45, 381-6.
105. Tarasenko, N.; Nudelman, A.; Tarasenko, I.; Entin-Meer, M.; Hass-Kogan, D, Inbal, A.; Rephaeli, A. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin. Exp. Metastasis, 2008, 25, 703-16.
106. Rephaeli, A.; Entin-Meer, M.; Angel, D.; Tarasenko, N.; Gruss-Fischer, T.; Bruachman, I.; Phillips D. R., Cutts, S. M.; Haas-Kogan, D.; Nudelman, A. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Invest. New Drugs, 2006, 24, 383-92.
107. Heidor, R., Ortega, J. F., de Conti, A.; Ong, T. P.; Moreno, F. S. Anticarcinogenic actions of tributyrin, a butyric acid prodrug. Curr. Drug Targets, 2012, 13, 1720-9.
108. de Conti, A.; Tryndyak, V.; Koturbash, I.; Heidor, R.; Kuroiwa-Trzmielina, J.; Ong, T. P.; Beland, F. A.; Moreno, F. S. Pogribny, I. P. The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway. Carcinogenesis, 2013, 34, 1900-6.
109. Kang, S. N.; Lee, E.; Lee, M. K.; Lim, S. J. Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma. Drug Deliv., 2011, 18, 143-9.
110. Srinivas, S. R.; Prasad, P. D.; Umapathy, N. S.; Ganapathy, V.; Shekhawat, P. S. Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 293, G1046-53.
111. Cummings, J. H.; Pomare, E. W.; Branch, W. J.; Naylor, C. P.; Macfarlane, G. T., Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut., 1987, 28, 1221-7.
112. Bergman, E. N. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol. Rev., 1990, 70, 567-90.
113. Argenzio, R. A.; Whipp, S. C. Inter-relationship of sodium, chloride, bicarbonate and acetate transport by the colon of the pig. J. Physiol., 1979, 295, 365-81.
114. Topping, D. L.; Illman, R. J.; Clarke, J. M.; Trimble, R. P.; Jackson, K. A.; Marsono, Y. Dietary fat and fiber alter large bowel and portal venous volatile fatty acids and plasma cholesterol but not biliary steroids in pigs. J. Nutr., 1993, 123, 133-43.
115. Glitso, L. V.; Brunsgaard, G.; Hojsgaard, S.; Sandstrom, B.; Bach Knudsen, K. E. Intestinal degradation in pigs of rye dietary fibre with different structural characteristics. Br. J. Nutr., 1998, 80, 457-68.
116. McNeil, N. I.; Cummings, J. H.; James, W. P. Rectal absorption of short chain fatty acids in the absence of chloride. Gut, 1979, 20, 400-3.
117. Kawamata, K.; Hayashi, H.; Suzuki, Y. Propionate absorption associated with bicarbonate secretion in vitro in the mouse cecum. Pflugers Arch., 2007, 454, 253-62.
118. Hadjiagapiou, C.; Schmidt, L.; Dudeja, P. K.; Layden, T. J.; Ramaswamy, K. Mechanism(s) of butyrate transport in Caco-2 cells: role of monocarboxylate transporter 1. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 279, G775-80.
119. Thangaraju, M.; Cresci, G.; Itagaki, S.; Mellinger, J.; Browning, D. D.; Berger, F. G.; Prasad, P. D.; Ganapathy, V. Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J. Gastrointest. Surg., 2008, 12, 1773-81.
120. Gupta, N.; Martin, P. M.; Prasad, P. D.; Ganapathy, V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci., 2006, 78, 2419-25.
121. Yabuuchi, H.; Tamai, I.; Sai, Y.; Tsuji, A. Possible role of anion exchanger AE2 as the intestinal monocarboxylic acid/anion antiporter. Pharm. Res., 1998, 15, 411-6.
122. Shin, H. J.; Anzai, N.; Enomoto, A.; He, X.; Kim do, K.; Endou, H.; Kanai, Y. Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate. Hepatology, 2007, 45, 1046-55.
123. Halestrap, A. P.; Meredith, D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch., 2004, 447, 619-28.
124. Yoon, H.; Fanelli, A.; Grollman, E. F.; Philp, N. J. Identification of a unique monocarboxylate transporter (MCT3) in retinal pigment epithelium. Biochem. Biophys. Res. Commun., 1997, 234, 90-4.
125. Dimmer, K. S.; Friedrich, B.; Lang, F.; Deitmer, J. W.; Broer, S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem. J., 2000, 350, 219-227.
126. Garcia, C. K.; Li, X.; Luna, J.; Francke, U. Cdna Cloning of the human monocarboxylate transporter-1 and chromosomal localization of the Slc16a1 locus to 1p13.2-P12. Genomics, 1994, 23, 500-503.
127. Cuff, M. A.; Shirazi-Beechey, S. P., The human monocarboxylate transporter, MCT1: Genomic organization and promoter analysis. Biochem Biophys Res Commun., 2002, 292, 1048-1056.
128. Jackson, V. N.; Price, N. T.; Carpenter, L.; Halestrap, A. P. Cloning of the monocarboxylate transporter isoform MCT2 from rat testis provides evidence that expression in tissues is species-specific and may involve post-transcriptional regulation. Biochem. J., 1997, 324, 447-453.
129. Iwanaga, T.; Takebe, K.; Kato, I.; Karaki, S. I.; Kuwahara, A. Cellular expression of monocarboxylate transporters (MCT) in the digestive tract of the mouse, rat, and humans, with special reference to slc5a8. Biomed. Res. (Tokyo), 2006, 27, 243-254.
130. Gill, R. K.; Saksena, S.; Alrefai, W. A.; Sarwar, Z.; Goldstein, J. L.; Carroll, R. E.; Ramaswamy, K.; Dudeja, P. K. Expression and membrane localization of MCT isoforms along the length of the human intestine. Am. J. Physiol. Cell Physiol., 2005, 289, C846-52.
131. Shimoyama, Y.; Kirat, D.; Akihara, Y.; Kawasako, K.; Komine, M.; Hirayama, K.; Matsuda, K.; Okamoto, M.; Iwano, H.; Kato, S.; Taniyama, H. Expression of monocarboxylate transporter 1 (MCT1) in the dog intestine. J. Vet. Med. Sci., 2007, 69, 599-604.
132. Orsenigo, M. N.; Tosco, M.; Bazzini, C.; Laforenza, U.; Faelli, A. A monocarboxylate transporter MCT1 is located at the basolateral pole of rat jejunum. Exp. Physiol., 1999, 84, 1033-42.
133. Kirat, D.; Kondo, K.; Shimada, R.; Kato, S. Dietary pectin upregulates monocaboxylate transporter 1 in the rat gastrointestinal tract. Exp. Physiol., 2009, 94, 422-33.
134. Wilson, M. C.; Meredith, D.; Bunnun, C.; Sessions, R. B.; Halestrap, A. P. Studies on the DIDS-binding site of monocarboxylate transporter 1 suggest a homology model of the open conformation and a plausible translocation cycle. J. Biol. Chem., 2009, 284, 20011-21.
135. Broer, S.; Schneider, H. P.; Broer, A.; Rahman, B.; Hamprecht, B.; Deitmer, J. W. Characterization of the monocarboxylate transporter 1 expressed in Xenopus laevis oocytes by changes in cytosolic pH. Biochem. J., 1998, 333 (Pt 1), 167-74.
136. Di Cosimo, S.; Ferretti, G.; Papaldo, P.; Carlini, P.; Fabi, A.; Cognetti, F., Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc.), 2003, 39, 157-74.
137. Sandler, R. S.; Halabi, S.; Baron, J. A.; Budinger, S.; Paskett, E.; Keresztes, R.; Petrelli, N.; Pipas, J. M.; Karp, D. D.; Loprinzi, C. L.; Steinbach, G.; Schilsky, R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New Engl. J. Med., 2003, 348, 883-890.
138. Half, E.; Arber, N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin. Pharmacother., 2009, 10, 211-9.
139. Kekuda, R.; Manoharan, P.; Baseler, W.; Sundaram, U. Monocarboxylate 4 mediated butyrate transport in a rat intestinal epithelial cell line. Dig. Dis. Sci., 2013; 58, 660-7.
140. Sepponen, K.; Ruusunen, M.; Pakkanen, J. A.; Pösö, A. R. Expression of CD147 and monocarboxylate transporters MCT1, MCT2 and MCT4 in porcine small intestine and colon. Vet J., 2007, 174, 122-8.
141. Gotanda, Y.; Akagi, Y.; Kawahara, A.; Kinugasa, T.; Yoshida, T.; Ryu, Y.; Shiratsuchi, I.; Kage, M.; Shirouzu, K. Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor. Anticancer Res., 2013, 33, 2941-7.
142. Thibault, R.; Shirazi-Beechey, S.; De Coppet, P.; Daly, K.; Bourreille, A.; Cuff, M.; Bonnet, C.; Mosnier, J. F.; Galmiche, J. P.; Segain, J. P. Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology, 2007, 133, 1916-1927.
143. Borthakur, A.; Anbazhagan, A. N.; Kumar, A.; Raheja, G.; Singh, V.; Ramaswamy, K.; Dudeja, P. K. The probiotic Lactobacillus plantarum counteracts TNF-{alpha}-induced downregulation of SMCT1 expression and function. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 299, G928-34.
144. Daly, K.; Cuff, M. A.; Fung, F.; Shirazi-Beechey, S. P. The importance of colonic butyrate transport to the regulation of genes associated with colonic tissue homoeostasis. Biochem. Soc. T., 2005, 33, 733-5.
145. Donohoe, D. R.; Garge, N.; Zhang, X.; Sun, W.; O'Connell, T. M.; Bunger, M. K.; Bultman, S. J. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab., 2011, 13, 517-26.
146. Rodriguez-Enriquez, S.; Marin-Hernandez, A.; Gallardo-Perez, J. C.; Carreno-Fuentes, L.; Moreno-Sanchez, R. Targeting of cancer energy metabolism. Mol. Nutr. Food Res., 2009, 53, 29-48.
147. Moreno-Sanchez, R.; Rodriguez-Enriquez, S.; Marin-Hernandez, A.; Saavedra, E, Energy metabolism in tumor cells. FEBS, J., 2007, 274, 1393-1418.
148. Macheda, M. L.; Rogers, S.; Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol., 2005, 202, 654-62.
149. Busk, M.; Horsman, M. R.; Kristjansen, P. E. G.; van der Kogel, A. J.; Bussink, J.; Overgaard, J. Aerobic glycolysis in cancers: Implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int. J. Cancer, 2008, 122, 2726-2734.
150. Cuff, M.; Dyer, J.; Jones, M.; Shirazi-Beechey, S. The human colonic monocarboxylate transporter Isoform 1: its potential importance to colonic tissue homeostasis. Gastroenterology, 2005, 128, 676-86.
151. Mazzanti, R.; Solazzo, M.; Fantappie, O.; Elfering, S.; Pantaleo, P.; Bechi, P.; Cianchi, F.; Ettl, A.; Giulivi, C. Differential expression proteomics of human colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290, G1329-38.
152. Izumi, H.; Torigoe, T.; Ishiguchi, H.; Uramoto, H.; Yoshida, Y.; Tanabe, M.; Ise, T.; Murakami, T.; Yoshida, T.; Nomoto, M.; Kohno, K. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat. Rev., 2003, 29, 541-9.
153. Koukourakis, M. I.; Giatromanolaki, A.; Harris, A. L.; Sivridis, E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res., 2006, 66, 632-637.
154. Pinheiro, C.; Longatto, A.; Scapulatempo, C.; Ferreira, L.; Martins, S.; Pellerin, L.; Rodrigues, M.; Alves, V. A. F.; Schmitt, F.; Baltazar, F. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch., 2008, 452, 139-146.
155. Boidot, R., Végran, F.; Meulle, A.; Le Breton, A.; Dessy, C.; Sonveaux, P.; Lizard-Nacol, S.; Feron, O. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res., 2012, 72, 939-48.
156. Ullah, M. S.; Davies, A. J.; Halestrap, A. P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem., 2006, 281, 9030-7.
157. Yang, H.; Zou, W.; Chen, B. Overexpression of CD147 in ovarian cancer is initiated by the hypoxic microenvironment. Cell Biol. Int., 2013, 37, 1139-42.
158. Kang, K. W.; Im, Y. B.; Go, W. J.; Han, H. K. C-myc amplification altered the gene expression of ABC-and SLC-transporters in human breast epithelial cells. Mol. Pharm., 2009, 6, 627-33.
159. Latham, T.; Mackay, L.; Sproul, D.; Karim, M.; Culley, J.; Harrison, D. J.; Hayward, L.; Langridge-Smith, P.; Gilbert, N.; Ramsahoye, B. H. Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Res., 2012, 40, 4794-803.
160. Pouyssegur, J.; Dayan, F.; Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 2006, 441, 437-443.
161. Sonveaux, P.; Vegran, F.; Schroeder, T.; Wergin, M. C.; Verrax, J.; Rabbani, Z. N.; De Saedeleer, C. J.; Kennedy, K. M.; Diepart, C.; Jordan, B. F.; Kelley, M. J.; Gallez, B.; Wahl, M. L.; Feron, O.; Dewhirst, M. W. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest., 2008, 118, 3930-3942.
162. Fang, J.; Quinones, Q. J.; Holman, T. L.; Morowitz, M. J.; Wang, Q.; Zhao, H.; Sivo, F.; Maris, J. M.; Wahl, M. L. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol. Pharmacol., 2006, 70, 2108-15.
163. Kennedy, K. M.; Dewhirst, M. W. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol., 2010, 6, 127-48.
164. Bueno, V.; Binet, I.; Steger, U.; Bundick, R.; Ferguson, D.; Murray, C.; Donald, D.; Wood, K. The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation, 2007, 84, 1204-1207.
165. Fishbein, W. N. Lactate transporter defect: a new disease of muscle. Science, 1986, 234, 1254-6.
166. Murray, C. M.; Hutchinson, R.; Bantick, J. R.; Belfield, G. P.; Benjamin, A. D.; Brazma, D.; Bundick, R. V.; Cook, I. D.; Craggs, R. I.; Edwards, S.; Evans, L. R.; Harrison, R.; Holness, E.; Jackson, A. P.; Jackson, C. G.; Kingston, L. P.; Perry, M. W. D.; Ross, A. R. J.; Rugman, P. A.; Sidhu, S. S.; Sullivan, M.; Taylor-Fishwick, D. A.; Walker, P. C.; Whitehead, Y. M.; Wilkinson, D. J.; Wright, A.; Donald, D. K. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat. Chem. Biol., 2005, 1, 371-376.
167. Le Floch, R.; Chiche, J.; Marchiq, I.; Naiken, T.; Ilk, K.; Murray, C. M.; Critchlow, S. E.; Roux, D.; Simon, M. P.; Pouyssegur, J. CD147 subunit of lactate/H(+) symporters MCT1 and hypoxiainducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. U.S.A., 2011, 108, 16663-16668.
168. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5, 769-84.
169. Sung, M. W.; Waxman, S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res., 2007, 27, 995-1001.
170. Boren, J.; Lee, W. N. P.; Bassilian, S.; Centelles, J. J.; Lim, S.; Ahmed, S.; Boros, L. G.; Cascante, M. The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J. Biol. Chem., 2003, 278, 28395-28402.
171. Alcarraz-Vizan, G.; Boren, J.; Lee, W. N. P.; Cascante, M. Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation. Metabolomics, 2010, 6, 229-237.
172. Blouin, J. M.; Penot, G.; Collinet, M.; Nacfer, M.; Forest, C.; Laurent-Puig, P.; Coumoul, X.; Barouki, R.; Benelli, C.; Bortoli, S. Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. Int. J. Cancer, 2011, 128, 2591-2601.
173. Hadjiagapiou, C.; Borthakur, A.; Dahdal, R. Y.; Gill, R. K.; Malakooti, J.; Ramaswamy, K.; Dudeja, P. K. Role of USF1 and USF2 as potential repressor proteins for human intestinal monocarboxylate transporter 1 promoter. Am. J. Physiol.Gastr. L., 2005, 288, G1118-G1126.
174. Dudeja, P. K.; Borthakur, A.; Saksena, S.; Gill, R. K.; Alrefai, W. A.; Ramaswamy, K. Regulation of monocarboxylate transporter 1 (MCT1) promoter by butyrate in human intestinal epithelial cells: Involvement of NF-kappa B pathway. J. Cell Biochem., 2008, 103, 1452-1463.
175. Saksena, S.; Dwivedi, A.; Gill, R. K.; Singla, A.; Alrefai, W. A.; Malakooti, J.; Ramaswamy, K.; Dudeja, P. K. PKC-dependent stimulation of the human MCT1 promoter involves transcription factor AP2. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296, G275-G283.
176. Benton, C. R.; Yoshida, Y.; Lally, J.; Han, X. X.; Hatta, H.; Bonen, A. PGC-1alpha increases skeletal muscle lactate uptake by increasing the expression of MCT1 but not MCT2 or MCT4. Physiol. Genomics, 2008, 35, 45-54.
177. Konig, B.; Koch, A.; Giggel, K.; Dordschbal, B.; Eder, K.; Stangl, G. I. Monocarboxylate transporter (MCT)-1 is up-regulated by PPAR alpha. Biochim. Biophys. Acta, 2008, 1780, 899-904.
178. Konig, B.; Fischer, S.; Schlotte, S.; Wen, G. P.; Eder, K.; Stangl, G. I. Monocarboxylate transporter 1 and CD147 are up-regulated by natural and synthetic peroxisome proliferator-activated receptor alpha agonists in livers of rodents and pigs. Mol. Nutr. Food Res., 2010, 54, 1248-1256.
179. Pullen, T. J.; da Silva Xavier, G.; Kelsey, G.; Rutter, G. A. miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol. Cell Biol., 2011, 31, 3182-94.
180. Biswas, C. Tumor-cell stimulation of collagenase production by fibroblasts. Biochem. Biophys. Res. Commun., 1982, 109, 1026-1034.
181. Wilson, M. C.; Meredith, D.; Fox, J. E. M.; Manoharan, C.; Davies, A. J.; Halestrap, A. P. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4-The ancillary protein for the insensitive MCT2 is embigin (gp70). J. Biol. Chem., 2005, 280, 27213-27221.
182. Galic, S.; Schneider, H. P.; Broer, A.; Deitmer, J. W.; Broer, S.The loop between helix 4 and helix 5 in the monocarboxylate transporter MCT1 is important for substrate selection and protein stability. Biochemical Journal., 2003, 376, 413-422.
183. Becker, H. M.; Hirnet, D.; Fecher-Trost, C.; Sultemeyer, D.; Deitmer, J. W. Transport activity of MCT1 expressed in Xenopus oocytes is increased by interaction with carbonic anhydrase. J. Biol. Chem., 2005, 280, 39882-39889.
184. Nguyen, T. T.; Bonanno, J. A. Bicarbonate, NBCe1, NHE, and carbonic anhydrase activity enhance lactate-H+ transport in bovine corneal endothelium. Invest. Ophth. Vis. Sci., 2011, 52, 8086-93.
185. Saksena, S.; Theegala, S.; Bansal, N.; Gill, R. K.; Tyagi, S.; Alrefai, W. A.; Ramaswamy, K.; Dudeja, P. K. Mechanisms underlying modulation of monocarboxylate transporter 1 (MCT1) by somatostatin in human intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 297, G878-G885.
186. Buyse, M.; Sitaraman, S. V.; Liu, X.; Bado, A.; Merlin, D. Luminal leptin enhances CD147/MCT-1-mediated uptake of butyrate in the human intestinal cell line Caco2-BBE. J. Biol. Chem., 2002, 277, 28182-28190.
187. Fanelli, A.; Grollman, E. F.; Wang, D.; Philp, N. J. MCT1 and its accessory protein CD147 are differentially regulated by TSH in rat thyroid cells. Am. J. Physiol.Endoc. Metab., 2003, 285, E1223-E1229.
188. Enoki, T.; Yoshida, Y.; Lally, J.; Hatta, H.; Bonen, A. Testosterone increases lactate transport, monocarboxylate transporter (MCT) 1 and MCT4 in rat skeletal muscle. J. Physiol., 2006, 577, 433-43.
189. Goncalves, P.; Martel, F.; Araujo, J. R.; Pinho, M. J. Modulation of butyrate transport in Caco-2 cells. Naunyn Schmiedebergs Arch. Pharmacol., 2009, 379, 325-336.
190. Stearns, A. T.; Balakrishnan, A.; Rhoads, D. B.; Ashley, S. W.; Tavakkolizadeh, A. Diurnal rhythmicity in the transcription of jejunal drug transporters. J. Pharmacol. Sci., 2008, 108, 144-8.
191. Borthakur, A.; Priyamvada, S.; Kumar, A.; Natarajan, A. A.; Gill, R. K.; Alrefai, W. A.; Dudeja, P. K. A novel nutrient sensing mechanism underlies substrate-induced regulation of monocarboxylate transporter-1. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 303, G1126-33.
192. Halestrap, A. P. Transport of pyruvate and lactate into human erythrocytes-evidence for involvement of chloride carrier and a chloride-independent carrier. Biochem. J., 1976, 156, 193-207.
193. Brooks, G. A.; Hashimoto, T.; Hussien, R.; Oommen, S.; Gohil, K. Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis. FASEB J., 2007, 21, 2602-2612.
194. Choi, J. S.; Jin, M. J.; Han, H. K. Role of monocarboxylic acid transporters in the cellular uptake of NSAIDs. J. Pharm. Pharmacol., 2005, 57, 1185-1189.
195. Goncalves, P.; Martel, F.; Araujo, J. R. Characterization of butyrate uptake by nontransformed intestinal epithelial cell lines. J. Membr. Biol., 2011, 240, 35-46.
196. Shim, C. K.; Cheon, E. P.; Kang, K. W.; Seo, K. S.; Han, H. K. Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in Caco-2 cells. J. Pharm. Pharmacol., 2007, 59, 1515-9.
197. Gonçalves, P.C.T.; Gregório, I.; Martel, F. In vitro studies on the inhibition of butyrate uptake by the primary bile salt chenodeoxycholic acid in a non-tumoral intestinal epithelial cell line (IEC-6 cells). J. Cell. Biochem., 2012, 113, 2937-47.
198. Borthakur, A.; Gill, R. K.; Hodges, K.; Ramaswamy, K.; Hecht, G.; Dudeja, P. K. Enteropathogenic Escherichia coli inhibits butyrate uptake in Caco-2 cells by altering the apical membrane MCT1 level. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290, G30-5.
199. Goncalves, P.; Martel, F.; Araujo, J. R. Effect of some natural mineral waters in nutrient uptake by Caco-2 cells. Int. J. Vitam Nutr. Res., 2010, 80, 131-143.
200. Rodriguez, A. M.; Perron, B.; Lacroix, L.; Caillou, B.; Leblanc, G.; Schlumberger, M.; Bidart, J. M.; Pourcher, T. Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J. Clin. Endocr. Metab., 2002, 87, 3500-3503.
201. Li, H.; Myeroff, L.; Smiraglia, D.; Romero, M. F.; Pretlow, T. P.; Kasturi, L.; Lutterbaugh, J.; Rerko, R. M., Casey, G.; Issa, J. P.; Willis, J.; Willson, J. K.; Plass, C.; Markowitz, S. D. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 8412-7
202. Zhang, Y.; Bao, Y. L.; Wu, Y.; Yu, C. L.; Sun, Y.; Li, Y. X. Identification and characterization of the human SLC5A8 gene promoter. Cancer Genet. Cytogenet., 2010, 196, 124-32.
203. Rodriguez, A. M.; Perron, B.; Lacroix, L.; Caillou, B.; Leblanc, G.; Schlumberger, M.; Bidart, J. M.; Pourcher, T. Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J. Clin. Endocrinol. Metab., 2002, 87, 3500-3.
204. Iwanaga, T.; Takebe, K.; Nio, J.; Morimatsu, M.; Karaki, S. I.; Kuwahara, A.; Kato, I. Histochemical demonstration of a Na+-coupled transporter for short-chain fatty acids (Slc5a8) in the intestine and kidney of the mouse. Biomed. Res. (Tokyo), 2005, 26, 213-221.
205. Ganapathy, V.; Gopal, E.; Miyauchi, S.; Martin, P. M.; Ananth, S.; Roon, P.; Smith, S. B. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharmaceut. Res., 2007, 24, 575-584.
206. Martin, P. M.; Gopal, E.; Ananth, S.; Zhuang, L.; Itagaki, S.; Prasad, B. M.; Smith, S. B.; Prasad, P. D.; Ganapathy, V. Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J. Neurochem., 2006, 98, 279-288.
207. Itagaki, S.; Gopal, E.; Zhuang, L. N.; Fei, Y. J.; Miyauchi, S.; Prasad, P. D.; Ganapathy, V. Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8). Pharmaceut. Res., 2006, 23, 1209-1216.
208. Miyauchi, S.; Gopal, E.; Babu, E.; Srinivas, S. R.; Kubo, Y.; Umapathy, N. S.; Thakkar, S. V.; Ganapathy, V.; Prasad, P. D. Sodiumcoupled electrogenic transport of pyroglutamate (5-oxoproline) via SLC5A8, a monocarboxylate transporter. Biochim. Biophys. Acta, 2010, 1798, 1164-71.
209. Miyauchi, S.; Gopal, E.; Fei, Y. J.; Ganapathy, V. Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na+-coupled transporter for short-chain fatty acids. J. Biol. Chem., 2004, 279, 13293-13296.
210. Coady, M. J.; Chang, M. H.; Charron, F. A.; Plata, C.; Wallendorff, B.; Sah, J. F.; Markowitz, S. D.; Romero, M. E.; Lapointe, J. Y. The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. J. Physiol. (Lond.), 2004, 557, 719-731.
211. Ganapathy, V.; Thangaraju, M.; Gopal, E.; Martin, P. M.; Itagaki, S.; Miyauchi, S.; Prasad, P. D. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS, J., 2008, 10, 193-199.
212. Segain, J. P.; Thibault, R.; Blachier, F.; Darcy-Vrillon, B.; de Coppet, P.; Bourreille, A. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm. Bowel Dis., 2010, 16, 684-695.
213. Giovannucci, E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 2001, 10, 725-31.
214. Doshi, M.; Takiue, Y.; Saito, H.; Hosoyamada, M. The increased protein level of URAT1 was observed in obesity/metabolic syndrome model mice. Nucleosides Nucleotides Nucleic Acids, 2011, 30, 1290-4.
215. Caligiuri, M. A.; Whitman, S. P.; Hackanson, B.; Liyanarachchi, S.; Liu, S.; Rush, L. J.; Maharry, K.; Margeson, D.; Davuluri, R.; Wen, J.; Witte, T.; Yu, L.; Liu, C.; Bloomfield, C. D.; Marcucci, G.; Plass, C. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood, 2008, 112, 2013-2016.
216. Whitman, S. P.; Hackanson, B.; Liyanarachchi, S.; Liu, S.; Rush, L. J.; Maharry, K.; Margeson, D.; Davuluri, R.; Wen, J.; Witte, T.; Yu, L.; Liu, C., Bloomfield, C. D.; Marcucci, G.; Plass, C.; Caligiuri, M. A. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood, 2008, 112, 2013-6.
217. Elangovan, S.; Pathania, R.; Ramachandran, S., Ananth, S.; Padia, R. N., Srinivas, S. R.; Babu, E., Hawthorn, L.; Schoenlein, P. V.; Boettger, T.; Smith, S. B.; Prasad, P. D.; Ganapathy, V.; Thangaraju, M. Molecular Mechanism of SLC5A8-Inactivation in Breast Cancer. Mol. Cell. Biol., 2013, in press.
218. Orita, H.; Sakamoto, N.; Ajioka, Y.; Terai, T.; Hino, O.; Sato, N.; Shimoda, T.; Kamano, T.; Tsurumaru, M.; Fujii, H. Allelic loss analysis of early-stage flat-type colorectal tumors. Ann. Oncol., 2006, 17, 43-9.
219. Aytekin, T.; Ozaslan, M.; Cengiz, B. Deletion mapping of chromosome region 12q13-24 in colorectal cancer. Cancer Genet. Cytogenet., 2010, 201, 32-8.
220. Kerr, C. A.; Dunne, R.; Hines, B. M.; Zucker, M.; Cosgrove, L.; Ruszkiewicz, A.; Lockett, T.; Head, R. Measuring the combinatorial expression of solute transporters and metalloproteinases transcripts in colorectal cancer. BMC Res. Notes, 2009, 2, 164.
221. Paroder, V.; Spencer, S. R.; Paroder, M.; Arango, D.; Schwartz, S Jr.; Mariadason, J. M.; Augenlicht, L.H.; Eskandari, S.; Carrasco, N. Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 7270-5.
222. Frank, H.; Groger, N.; Diener, M.; Becker, C.; Braun, T.; Boettger, T. Lactaturia and loss of sodium-dependent lactate uptake in the colon of SLC5A8-deficient mice. J. Biol. Chem., 2008, 283, 24729-37.
223. Thibault, R.; Blachier, F.; Darcy-Vrillon, B.; de Coppet, P.; Bourreille, A.; Segain, J. P. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis., 2010, 16, 684-95.
224. Coothankandaswamy, V.; Elangovan, S.; Singh, N.; Prasad, P. D.; Thangaraju, M.; Ganapathy, V. The plasma membrane transporter SLC5A8 suppresses tumor progression through depletion of survivin without involving its transport function. Biochem. J., 2013, 450, 169-78.
225. Gonçalves, P.; Gregório, I.; Catarino, T.A.; Martel, F. The effect of oxidative stress upon the intestinal epithelial uptake of butyrate. Eur. J. Pharmacol., 2013, 699, 88-100.
226. Ganapathy, V.; Cresci, G. A.; Thangaraju, M.; Mellinger, J. D.; Liu, K. B. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J. Gastrointest. Surg., 2010, 14, 449-461.
227. Ananth, S.; Zhuang, L.; Gopal, E.; Itagaki, S.; Ellappan, B.; Smith, S. B.; Ganapathy, V.; Martin, P. Diclofenac-induced stimulation of SMCT1 (SLC5A8) in a heterologous expression system: a RPE specific phenomenon. Biochem. Biophys. Res. Commun., 2010, 394, 75-80.
228. Bao, Y. L.; Zhang, Y.; Yang, M. T.; Wu, Y.; Yu, C. L.; Huang, Y. X.; Sun, Y.; Zheng, L. H.; Li, Y. X. Activin A induces SLC5A8 expression through the Smad3 signaling pathway in human colon cancer RKO cells. Int. J. Biochem. Cell B, 2010, 42, 1964-1972.
229. Dietrich, C. G.; Vehr, A. K.; Martin, I. V.; Gassler, N.; Rath, T.; Roeb, E.; Schmitt, J.; Trautwein, C.; Geier, A. Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen. Int. J. Cancer, 2011, 129, 546-52.
230. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 15665-70.
231. Maliepaard, M.; Scheffer, G. L.; Faneyte, I. F.; van Gastelen, M. A.; Pijnenborg, A. C. L. M.; Schinkel, A. H.; van de Vijver, M. J.; Scheper, R. J.; Schellens, J. H. M. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 2001, 61, 3458-3464.
232. Gonçalves, P.; Gregório, I.; Martel, F. The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein (BCRP) Am J Physiol Cell Physiol., 2011, 301, C984-94.
233. Englund, G.; Jacobson, A.; Rorsmon, F.; Artursson, P.; Kindmark, A.; Ronnblom, A. Efflux transporters in ulcerative colitis: Decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm. Bowel Dis., 2007, 13, 291-297.
234. Gutmann, H.; Hruz, P.; Zimmermann, C.; Straumann, A.; Terracciano, L.; Hammann, F.; Lehmann, F.; Beglinger, C.; Drewe, J. Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls. Digestion, 2008, 78, 154-162.
235. Deuring, J. J.; de Haar, C.; Koelewijn, C. L.; Kuipers, E. J.; Peppelenbosch, M.; van der Woude, C. J. Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding. Biochem J., 2011, 441, 87-93.
236. Gupta, N.; Martin, P. M.; Miyauchi, S.; Ananth, S.; Herdman, A. V.; Martindale, R. G.; Podolsky, R.; Ganapathy, V. Downregulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochem Biophys Res Commun., 2006, 343, 571-577.
237. Chikazawa, N.; Tanaka, H.; Tasaka, T.; Nakamura, M.; Tanaka, M.; Onishi, H.; Katano, M. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res., 2010, 30, 2041-8.
238. Pandurangan, A. K. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac. J. Cancer Prev., 2013, 14, 2201-5.
239. Sparks, A. B.; Morin, P. J.; Vogelstein, B.; Kinzler, K. W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res., 1998, 58, 1130-4.
240. Imai, Y.; Nakane, M.; Kage, K.; Tsukahara, S.; Ishikawa, E.; Tsuruo, T.; Miki, Y.; Sugimoto, Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther., 2002, 1, 611-6.
241. Zamber, C. P.; Lamba, J. K.; Yasuda, K.; Farnum, J.; Thummel, K.; Schuetz, J. D.; Schuetz, E. G. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics, 2003, 13, 19-28.
242. Ebert, B.; Seidel, A.; Lampen, A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis, 2005, 26, 1754-1763.
243. Pavek, P.; Merino, G.; Wagenaar, E.; Bolscher, E.; Novotna, M.; Jonker, J. W.; Schinkel, A. H. Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6- phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther., 2005, 312, 144-152.
244. Haraguchi, N.; Utsunomiya, T.; Inoue, H.; Tanaka, F.; Mimori, K.; Barnard, G. F.; Mori, M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells, 2006, 24, 506-513.
245. Zen, Y.; Fujii, T.; Yoshikawa, S.; Takamura, H.; Tani, T.; Ohta, T.; Nakanuma, Y. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am. J. Pathol., 2007, 170, 1750-1762.
246. Liu, H. G.; Pan, Y. F.; You, J.; Wang, O. C.; Huang, K. T.; Zhang, X. H. Expression of ABCG2 and its Significance in Colorectal Cancer. Asian Pac. J. Cancer P., 2010, 11, 845-848.
247. Nakanishi, T.; Ross, D. D. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin. J. Cancer, 2011, 31, 73-99.
248. Krishnamurthy, P.; Schuetz, J. D. The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival. Biometals., 2005, 18, 349-58.
249. Anapolsky, A.; Teng, S.; Dixit, S.; Piquette-Miller, M. The role of pregnane X receptor in 2-acetylaminofluorene-mediated induction of drug transport and-metabolizing enzymes in mice. Drug Metab. Dispos., 2006, 34, 405-9.
250. Sarkadi, B.; Homolya, L.; Szakacs, G.; Varadi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev., 2006, 86, 1179-236.
251. Ford, J. M.; Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 1990, 42, 155-199.
252. Sugimoto, Y.; Tsukahara, S.; Ishikawa, E.; Mitsuhashi, J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci., 2005, 96, 457-65.
253. Donohoe, D. R.; Collins, L. B.; Wali, A.; Bigler, R.; Sun, W.; Bultman, S. J. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol. Cell, 2012, 48, 612-26.
254. Noguchi, K.; Katayama, K.; Mitsuhashi, J.; Sugimoto, Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev., 2009, 61, 26-33.
255. Mao, Q. C.; Unadkat, J. D. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J., 2005, 7, E118-E133.
256. Pick, A.; Klinkhammer, W.; Wiese, M. Specific Inhibitors of the Breast Cancer Resistance Protein (BCRP). Chem. Med. Chem., 2010, 5, 1498-1505.
257. Bras-Goncalves, R. A.; Pocard, M.; Formento, J. L.; Poirson-Bichat, F.; De Pinieux, G.; Pandrea, I.; Arvelo, F.; Ronco, G.; Villa, P.; Coquelle, A.; Milano, G.; Lesuffleur, T.; Dutrillaux, B.; Poupon, M. F. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology, 2001, 120, 874-888.
258. Kripke, S.A., et al., Stimulation of intestinal mucosal growth with intracolonic infusion of short-chain fatty acids. JPEN. Journal of parenteral and enteral nutrition, 1989, 13(2), 109-16.
259. Sakata, T.; von Engelhardt, W. Stimulatory effect of short chain fatty acids on the epithelial cell proliferation in rat large intestine. Comp. Biochem. Physiol. A Comp. Physiol., 1983, 74, 459-62.
260. Heerdt, B.G.; Houston, M. A.; Augenlicht, L.H. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res., 1994, 54, 3288-93.
261. Hofmanova, J.; Vaculova, A.; Koubkova, Z.; Hyzd'alova, M.; Kozubik, A. Human fetal colon cells and colon cancer cells respond differently to butyrate and PUFAs. Mol. Nutr. Food Res., 2009, 53 Suppl 1, S102-13.
262. Serpa, J.; Caiado, F.; Carvalho, T.; Torre, C.; Goncalves, L. G.; Casalou, C.; Lamosa, P.; Rodrigues, M.; Zhu, Z. P.; Lam, E. W. F.; Dias, S. Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells. J. Biol. Chem., 2010, 285, 39211-39223.
263. Donohoe, D. R.; Wali, A.; Brylawski, B. P.; Bultman, S. J. Microbial regulation of glucose metabolism and cell-cycle progression in mammalian colonocytes. PLoS One., 2012, 7, e46589.
264. Burgess, D. J. Metabolism: Warburg behind the butyrate paradox? Nat. Rev. Cancer, 2012, 12, 798.
265. Goncalves, P.; Catarino, T.; Gregorio, I.; Martel, F. Inhibition of butyrate uptake by the primary bile salt chenodeoxycholic acid in intestinal epithelial cells. J. Cell Biochem., 2012, 113, 2937-47.
266. Andriamihaja, M.; Chaumontet, C.; Tome, D.; Blachier, F. Butyrate metabolism in human colon carcinoma cells: implications concerning its growth-inhibitory effect. J. Cell Physiol., 2009, 218, 58-65.
267. Sakata, T. Stimulatory effect of short-chain fatty acids on epithelial cell proliferation in the rat intestine: a possible explanation for trophic effects of fermentable fibre, gut microbes and luminal trophic factors. Br. J. Nutr., 1987, 58, 95-103.
268. Scheppach, W.; Bartram, P.; Richter, A.; Richter, F.; Liepold, H.; Dusel, G.; Hofstetter, G.; Ruthlein, J.; Kasper, H. Effect of shortchain fatty acids on the human colonic mucosa in vitro. JPEN J Parenter. Enteral Nutr., 1992, 16, 43-8.
269. Mariadason, J. M.; Velcich, A.; Wilson, A. J.; Augenlicht, L. H.; Gibson, P. R. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology, 2001, 120, 889-99.
270. Hodin, R. A.; Meng, S. F.; Archer, S.; Tang, R. Cellular growth state differentially regulates enterocyte gene expression in butyratetreated HT-29 cells. Cell Growth Differ, 1996, 7, 647-653.